OBJECTIVES: To determine the frequency of serious pulmonary and hepatic adverse events (AEs) in persons aged 65 and older prescribed nitrofurantoin. DESIGN: Retrospective electronic health record (EHR) audit of nitrofurantoin prescriptions and associated AEs. SETTING: Urban academic medical center. PARTICIPANTS: All inpatients and outpatients aged 65 and older prescribed nitrofurantoin from January 1, 2010, to December 31, 2014. MEASUREMENTS: The number of nitrofurantoin prescriptions and pulmonary and hepatic AEs associated with nitrofurantoin use was acquired by data extraction from EHRs. RESULTS: Of 3,400 individuals aged 65 and older prescribed nitrofurantoin during the study period, 641 were identified as possibly having one of five targeted symptoms or disease complications (pulmonary and hepatic) associated with nitrofurantoin. After a detailed chart audit, 89% were deemed to have no adverse reaction, 7% had a minor side effect or allergy, and 3.9% met criteria for suspicion of a nitrofurantoin-induced AE, five of whom were rated as being highly suspicious for nitrofurantoin toxicity; four of the five were identified with pulmonary toxicity and one with hepatotoxicity. Four of five of these individuals used nitrofurantoin chronically. CONCLUSION: Nitrofurantoin was prescribed for 3,400 individuals aged 65 and older during the 5-year study period. Serious side effects appeared to be uncommon, but chronic use appeared to be at greater risk.
OBJECTIVES: To determine the frequency of serious pulmonary and hepatic adverse events (AEs) in persons aged 65 and older prescribed nitrofurantoin. DESIGN: Retrospective electronic health record (EHR) audit of nitrofurantoin prescriptions and associated AEs. SETTING: Urban academic medical center. PARTICIPANTS: All inpatients and outpatients aged 65 and older prescribed nitrofurantoin from January 1, 2010, to December 31, 2014. MEASUREMENTS: The number of nitrofurantoin prescriptions and pulmonary and hepatic AEs associated with nitrofurantoin use was acquired by data extraction from EHRs. RESULTS: Of 3,400 individuals aged 65 and older prescribed nitrofurantoin during the study period, 641 were identified as possibly having one of five targeted symptoms or disease complications (pulmonary and hepatic) associated with nitrofurantoin. After a detailed chart audit, 89% were deemed to have no adverse reaction, 7% had a minor side effect or allergy, and 3.9% met criteria for suspicion of a nitrofurantoin-induced AE, five of whom were rated as being highly suspicious for nitrofurantointoxicity; four of the five were identified with pulmonary toxicity and one with hepatotoxicity. Four of five of these individuals used nitrofurantoin chronically. CONCLUSION:Nitrofurantoin was prescribed for 3,400 individuals aged 65 and older during the 5-year study period. Serious side effects appeared to be uncommon, but chronic use appeared to be at greater risk.
Authors: Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper Journal: Clin Infect Dis Date: 2011-03-01 Impact factor: 9.079
Authors: C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt Journal: Clin Pharmacol Ther Date: 1981-08 Impact factor: 6.875
Authors: Angela Huttner; Els M Verhaegh; Stephan Harbarth; Anouk E Muller; Ursula Theuretzbacher; Johan W Mouton Journal: J Antimicrob Chemother Date: 2015-06-11 Impact factor: 5.790
Authors: Namisha Singh; Sonja Gandhi; Eric McArthur; Louise Moist; Arsh K Jain; Aiden R Liu; Manish M Sood; Amit X Garg Journal: CMAJ Date: 2015-04-27 Impact factor: 8.262
Authors: Adrian Wong; Diane L Seger; Kenneth H Lai; Foster R Goss; Kimberly G Blumenthal; Li Zhou Journal: J Allergy Clin Immunol Pract Date: 2018-12-01
Authors: Joseph T Hanlon; Subashan Perera; Paul J Drinka; Christopher J Crnich; Steven J Schweon; Michele Klein-Fedyshin; Charles B Wessel; Stacey Saracco; Gulsum Anderson; Mary Mulligan; David A Nace Journal: J Am Geriatr Soc Date: 2018-12-24 Impact factor: 5.562
Authors: Carolina Orlando Vaso; Níura Madalena Bila; Fabiana Pandolfi; Daniela De Vita; Martina Bortolami; Jean Lucas Carvalho Bonatti; Rosângela Aparecida De Moraes Silva; Larissa Naiara Carvalho Gonçalves; Valeria Tudino; Roberta Costi; Roberto Di Santo; Maria José Soares Mendes-Giannini; Caroline Barcelos Costa-Orlandi; Luigi Scipione; Ana Marisa Fusco-Almeida Journal: Pharmaceutics Date: 2022-05-12 Impact factor: 6.525
Authors: Toby Peter Speirs; Nicole Tuffin; Finlay Mundy-Baird; Helena Sakota; Sarah Mulholland; Michelle Westlake; Max Lyon; Andrew R Medford; Charles Sharp; Michael Darby; Mahableshwar Albur; Francis Keeley; Helena Burden; Charlie Kenward; Elizabeth Jonas; Shaney Barratt; Huzaifa I Adamali Journal: BJGP Open Date: 2021-12-14